Syros Pharmaceuticals

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31
Revenue
$0
$0
$386
Gross Profit
-331
-334
107
EBITDA
-27,085
-30,587
-26,726
EBIT
-27,416
-30,921
-27,005
Net Income
-23,327
-3,708
-64,384
Net Change In Cash
0
0
386
Free Cash Flow
-29,667
-31,098
-18,603
Cash
78,964
83,523
139,526
Basic Shares
39,269
38,978
29,541

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$9,936
$14,880
$23,488
$15,093
Gross Profit
7,684
11,913
23,488
15,093
EBITDA
-124,247
-130,774
-96,315
-78,836
EBIT
-126,499
-133,741
-99,333
-81,871
Net Income
-164,574
-49,301
-90,465
-85,830
Net Change In Cash
9,936
14,880
23,488
15,093
Cost of Revenue
75,165
132,253
Free Cash Flow
-110,044
-124,306
-100,785
-60,700
Cash
139,526
167,467
92,302
173,984
Basic Shares
28,325
12,631
6,253
4,605

Earnings Calls

Quarter EPS
2024-09-30
-$0.16
2024-06-30
-$0.59
2024-03-31
-$0.10
2023-12-31
-$2.18